News - Generics, Eli Lilly


Current filters:

GenericsEli Lilly

Popular Filters

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved

Mylan debuts generic Zyprexa Zydis in USA; Actavis Exalgo copy approved


US generic drugmaker Mylan says it has launched Olanzapine Orally Disintegrating tablets (ODT), 5mg,…

ActavisEli LillyExalgoGenericsMallinckrodtMarkets & MarketingMylanNeurologicalRegulationUSAZyprexa

Prasco to market the authorized generic of Lilly’s Evista in USA


Privately-held US generics firm Prasco has signed a further deal with US pharma major Eli Lilly to market…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsMarkets & MarketingNorth AmericaPrasco LaboratoriesUSA

Teva gains approval for generic Evista in the USA

Teva gains approval for generic Evista in the USA


Israel-based Teva Pharmaceutical Industries says it has received approval from the US Food and Drug Administration…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsNorth AmericaRegulationTeva Pharmaceutical IndustriesUSA

Actavis confirms challenge of Lilly’s Axiron patent

Actavis confirms challenge of Lilly’s Axiron patent


US generics major Actavis confirms that it has filed an Abbreviated New Drug Application with the US…

ActavisAxironEli LillyGenericsLegalMen's HealthNorth AmericaPatentsRegulation

Lundbeck/Takeda's Brintellix has blockbuster potential


Denmark CNS drug specialist Lundbeck (LUND: CO) and partner Japanese drug major Takeda Pharmaceutical's…

BrintellixedivoxetineEli LillyFetzimaForest LaboratoriesGenericsGlobalLundbeckMarkets & MarketingNeurologicalPharmaceuticalPierre FabreTakeda Pharmaceuticals

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J


Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

Mylan extends deal with Bioton to biosimilar insulins, as Actavis pulls out of JV


US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement…

ActavisBiotechnologyBiotonDiabetesEli LillyGenericsHumalogLantusLicensingMarkets & MarketingMylan LaboratoriesNovo NordiskNovoLogSanofi

Eli Lilly in deal with Strides Arcolab for cancer drugs in emerging markets


US pharma major Eli Lilly (NYSE: LLY) and Indian drugmaker Strides Arcolab (BO: 532531) have entered…

Asia-PacificEli LillyGenericsLicensingMarkets & MarketingStrides Arcolab

Lilly to increase equity position in China's Novast by $20 million


US pharma major Eli Lilly (NYSE: LLY) says it will increase of its network of manufacturing capabilities…

Asia-PacificEli LillyGenericsMergers & AcquisitionsNovast LaboratoriesPharmaceutical

Prasco selected as Eli Lilly authorized generics partner for Zyprexa


Privately-held US drugmaker Prasco Laboratories says it has signed a marketing and distribution agreement…

Eli LillyGenericsMarkets & MarketingNeurologicalNorth AmericaPrasco LaboratoriesZyprexa

Actavis brings generic Zyprexa to further 11 markets; misses out on buying Polfa


Iceland-headquartered generic drugmaker Actavis Group last week started marketing olanzapine tablets,…

ActavisEli LillyEuropeGenericsMarkets & MarketingMergers & AcquisitionsOlanzapinePolfa WarszawaPolpharmaZyprexa

Hospira gains US approval of solution version of gemcitabine injection


US generic injectable drug leader Hospira (NYSE: HSP) says the US Food and Drug Administration has approved…

Eli Lillygemcitabine HclGemzarGenericsHospiraNorth AmericaOncologyRegulation

Back to top